ASTRO: Patient Experience of Radiation Better Than Expected

Share this content:
ASTRO: Patient Experience of Radiation Better Than Expected
ASTRO: Patient Experience of Radiation Better Than Expected

THURSDAY, Sept. 28, 2017 (HealthDay News) -- Most patients with breast cancer treated with radiation therapy (RT) report that their experience was less scary than they expected, according to a study presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held from Sept. 24 to 27 in San Diego.

Narek Shaverdian, M.D., from the University of California, Los Angeles, and colleagues surveyed 327 patients with breast cancer treated from 2012 to 2016 about their pre-treatment RT beliefs compared with their actual experience.

The researchers found that at the time of diagnosis, the most feared treatment was chemotherapy, surgery, RT, and endocrine therapy for 55, 36, 7, and 5 percent of patients, respectively. Sixty-eight percent of patients reported having little to no knowledge about RT initially; 47 percent reported that they had heard or read frightening stories. Damage to internal organs, skin burning, and being radioactive were the most commonly ranked fears about RT (40, 24, and 7 percent, respectively). Overall, 83 and 84 percent reported short-term and long-term side effects to be better than or as expected, respectively. Only 2 and 3 percent of women agreed that the negative stories they had initially heard and read were actually true; 90 percent agreed that their experience was less scary than expected.

"The negative stories out there are frightening and pervasive, but they generally are not reflective of the actual experience," one of the co-authors said in a statement.

News Release/Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »